Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
CSBTA Pharmacokinetics in MASH Mice
2026-09-08
The reference study integrates plasma pharmacokinetics, tissue distribution, transporter assays, and metabolic-enzyme analysis to explain how HFHCD-induced MASH changes the disposition of Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic exposure, hepatic distribution, and hepatocyte accumulation, with CYP450 enzymes, Oatp1b2, P-gp, and PXR implicated in the variability.
-
CX-5461: From Pol I Blockade to Assay Design
2026-09-08
CX-5461 is an RNA polymerase I inhibitor that connects ribosome biogenesis stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This article presents a practical assay framework for interpreting its activity in cancer research beyond simple viability measurements.
-
Bicinchoninic Acid Assay (BCA) Kit Guide
2026-09-07
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, measures low-concentration total protein in biochemical samples and cell lysates, including many detergent-containing preparations. It is intended for scientific research and sample-normalization workflows, not diagnostic, clinical, or medical testing.
-
CKI 7 Dihydrochloride: CK1 Inhibitor Guide
2026-09-07
CKI 7 dihydrochloride is an ATP-competitive Casein kinase 1 inhibitor for controlled studies of CK1-dependent phosphorylation. Its defined identity, solubility limits, and storage requirements support biochemical, Wnt, circadian, and cancer biology research, but the compound does not by itself establish pathway specificity or therapeutic activity.
-
Glycogen Colorimetric Assay Kit II for Exercise Studies
2026-09-05
The Glycogen Colorimetric Assay Kit II provides a practical way to compare liver and muscle glycogen across training time points, circadian phases, and metabolic models. Its hydrolysis-based, 450 nm readout is especially useful when reducing substances make conventional oxidase-based measurements difficult.
-
2,2,2-Trichloroethanol for Orthogonal Protein Assays
2026-09-04
Discover how 2,2,2-Trichloroethanol can support protein-level quality control without being confused with a dopamine imaging tracer. This evidence-focused guide connects electrophoretic analysis with the longitudinal DAT imaging strategy reported in a preclinical Parkinson’s disease model.
-
Trilaurin: Practical Lab Protocols
2026-09-04
Trilaurin, also called Glycerol Tridodecanoate, provides a defined C12 triacylglycerol for solvent-based formulation studies and enzymatic substrate screening. It should be treated as a research reagent rather than assumed to improve oral delivery, immune responses, or therapeutic outcomes without matched validation, particularly because it is water-insoluble and directly matched paper evidence is not available here.
-
EZ Cap™ EPO mRNA: A Decision Framework
2026-09-03
EZ Cap™ EPO mRNA supports controlled human erythropoietin expression in erythropoiesis, neuroprotection, and protein expression studies. This article presents an assay-centered framework for selecting controls, delivery systems, readouts, and interpretation boundaries rather than treating mRNA design as a standalone variable.
-
Decitabine Priming Expands Progenitor Tex in PD-1 Therapy
2026-09-03
Li et al. show that low-dose Decitabine, also known as 5-Aza-2'-deoxycytidine, improves anti–PD-1 activity by expanding and functionally maintaining CD8+ progenitor exhausted T cells rather than simply increasing short-term T-cell activation. The study connects epigenetic priming to sustained JunD and JNK/AP-1 activity, offering a mechanistic framework for combination immunotherapy research.
-
MCC950 Sodium for NLRP3 Assay Workflows
2026-09-02
MCC950 sodium, also known as CRID3 sodium salt, enables selective NLRP3 inflammasome inhibition across macrophage, neuroinflammation, and autoimmune disease workflows. This guide connects robust cell-based assay design with the astrocyte-focused morphine-tolerance findings reported in a 2024 reference study.
-
Phenytoin for Sodium Channel and Myelin Assays
2026-09-02
Phenytoin provides a practical pharmacological lever for voltage-gated sodium channel pathway studies, from controlled electrophysiology assay development to longitudinal models of myelin injury. Its strongest use-case is as one component of a paired activity-modulation workflow that separates reversible myelin swelling from irreversible sheath loss.
-
Iptacopan Monotherapy in PNH: Study Analysis
2026-09-01
This phase 2 proof-of-concept study evaluated oral Iptacopan (LNP023), a selective factor B inhibitor, as monotherapy in treatment-naive patients with active paroxysmal nocturnal hemoglobinuria. Rapid reductions in hemolysis, improved hemoglobin, and fewer transfusions support proximal alternative-pathway inhibition while the small, open-label design limits definitive comparisons with established therapies.
-
Cisapride in Predictive Cardiac Screening
2026-09-01
Cisapride, also known as R 51619, links 5-HT4 receptor pharmacology with hERG-centered cardiac safety testing. This practical guide shows how to deploy it in iPSC-cardiomyocyte, high-content imaging, and orthogonal electrophysiology workflows while separating functional, structural, and solvent-related effects.
-
MK-571 (L-660,711) Assay Workflows
2026-08-31
MK-571 (L-660,711) supports two complementary research strategies: blocking cysteinyl leukotriene signaling in airway models and probing ABCC1/MRP1-linked drug handling in macrophages. This guide combines concentration planning, controls, workflow enhancements, and troubleshooting so investigators can separate receptor antagonism from transporter and redox effects.
-
Axitinib (AG 013736): VEGFR Research Guide
2026-08-31
Axitinib (AG 013736) is a selective VEGFR1/2/3 tyrosine kinase inhibitor with subnanomolar biochemical potency. Its strongest research applications are VEGF signaling pathway modulation, angiogenesis inhibition assays, and tumor growth inhibition in xenograft models.